Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs

Long-acting injectable aripiprazole has substantiated safety and efficacy in treating schizophrenia. However, interindividual variability in clinical response to aripiprazole, possibly linked to its D2 partial agonism and D2 upregulation due to prior antipsychotics, has been reported. This study assessed whether there would be symptomatic aggravations or adverse events in clinically stable patients with schizophrenia when switching from oral antipsychotics to aripiprazole once-monthly (AOM), considering prior antipsychotics: oral aripiprazole (Group I) or other D2 antagonists (Group II). This was a 20-week, prospective, open-label, multicenter trial. Clinically stable patients with schizophrenia were assigned to two groups based on their oral antipsychotic medication and received AOM every 4 weeks. The primary endpoint was a change from baseline in the total Positive and Negative Syndrome Scale (PANSS) score. Treatment-emergent adverse events (TEAEs) were monitored. Altogether, 100 patients in Group I and 101 in Group II completed the study. The mean changes (±SD) from baseline in PANSS total score after switching to AOM were - 9.43 ± 9.79 in Group I (p < 0.0001) and - 4.04 ± 8.72 in Group II (p = 0.0102). Compared to Group I, in Group II, more sleep disturbance (p = 0.0243) and psychotic symptoms (p = 0.0042) TEAE emerged after AOM initiation, with both TEAEs resolving during the study. Psychotic symptoms TEAE was associated with faster tapering of the prior oral antipsychotics (p = 0.0269). Initiating AOM did not aggravate symptoms. Furthermore, AOM ameliorated psychotic symptoms without any significant adverse effect, regardless of their prior oral antipsychotics. However, patients previously treated with D2 antagonists may experience transient psychiatric TEAEs that can be minimized with longer cross-titration.

Authors

Institutions

Publication Details

Journal
Schizophrenia Research
Published
2025-05-17
DOI
https://doi.org/10.1016/j.schres.2025.04.033
Citations
1
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs

Young‐Chul Chung, Euitae Kim, Jun Soo Kwon, Ji Hyun Baek et al.
1 citations
Schizophrenia Research
Schizophrenia research and treatment
1.47
article

Stability of psychotic symptoms and safety in switching to aripiprazole once-monthly according to prior oral antipsychotic drugs

Young‐Chul Chung, Euitae Kim, Jun Soo Kwon, Ji Hyun Baek, Eun‐Jin Cheon, Sung‐Joon Cho, Christoph Ulrich Correll, Bong Ju Lee, Kyoung‐Uk Lee, Beomwoo Nam, Chang Hwa Lee, Seunghee Won, Soo In Kim, Sung‐Wan Kim, Seoyoung C. Kim, Sungwon Jung, Tai Kiu Choi
article en
1 citations

Abstract

Long-acting injectable aripiprazole has substantiated safety and efficacy in treating schizophrenia. However, interindividual variability in clinical response to aripiprazole, possibly linked to its D2 partial agonism and D2 upregulation due to prior antipsychotics, has been reported. This study assessed whether there would be symptomatic aggravations or adverse events in clinically stable patients with schizophrenia when switching from oral antipsychotics to aripiprazole once-monthly (AOM), considering prior antipsychotics: oral aripiprazole (Group I) or other D2 antagonists (Group II). This was a 20-week, prospective, open-label, multicenter trial. Clinically stable patients with schizophrenia were assigned to two groups based on their oral antipsychotic medication and received AOM every 4 weeks. The primary endpoint was a change from baseline in the total Positive and Negative Syndrome Scale (PANSS) score. Treatment-emergent adverse events (TEAEs) were monitored. Altogether, 100 patients in Group I and 101 in Group II completed the study. The mean changes (±SD) from baseline in PANSS total score after switching to AOM were - 9.43 ± 9.79 in Group I (p < 0.0001) and - 4.04 ± 8.72 in Group II (p = 0.0102). Compared to Group I, in Group II, more sleep disturbance (p = 0.0243) and psychotic symptoms (p = 0.0042) TEAE emerged after AOM initiation, with both TEAEs resolving during the study. Psychotic symptoms TEAE was associated with faster tapering of the prior oral antipsychotics (p = 0.0269). Initiating AOM did not aggravate symptoms. Furthermore, AOM ameliorated psychotic symptoms without any significant adverse effect, regardless of their prior oral antipsychotics. However, patients previously treated with D2 antagonists may experience transient psychiatric TEAEs that can be minimized with longer cross-titration.

Schizophrenia ResearchVol. 281
Chonnam National University (KR), Ewha Womans University (KR), Eulji University (KR), Konkuk University (KR), Samsung Medical Center (KR), New Generation University College (ET), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), Kyungpook National University (KR), Inje University Haeundae Paik Hospital (KR), Kangbuk Samsung Hospital (KR), The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR), Daejeon Eulji Medical Center, Eulji University (KR), Keimyung University Dongsan Medical Center (KR), CHA University Bundang Medical Center (KR), Yeungnam University Medical Center (KR), Zucker Hillside Hospital (US), Keimyung University (KR), Jeonbuk National University (KR), Sungkyunkwan University (KR)
Otsuka Pharmaceutical, Otsuka Pharmaceutical Development and Commercialization
Good health and well-being
Openalex Percentile: Top 19%
Schizophrenia research and treatment
1.47
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.